doramapimod

p38 MAP kinase inhibitor

Also Known As:

1-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-3-(4-(2-(morpholin-4-yl)ethoxy)naphthalen-1-yl)urea; 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3(4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl)urea; BIRB 796; BIRB 796 BS; BIRB-796; BIRB-796 BS; BIRB796

Networked: 32 relevant articles (3 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Singh, Dave: 3 articles (01/2020 - 01/2017)
2.	Zhang, Jing: 2 articles (05/2022 - 09/2021)
3.	Tudor, Elizabeth: 2 articles (09/2020 - 02/2020)
4.	Lea, Simon: 2 articles (01/2020 - 10/2017)
5.	Ito, Kazuhiro: 2 articles (11/2019 - 10/2017)
6.	Bagley, Mark C: 2 articles (06/2010 - 11/2006)
7.	Davis, Terence: 2 articles (06/2010 - 11/2006)
8.	Kipling, David: 2 articles (06/2010 - 11/2006)
9.	Widdowson, Caroline S: 2 articles (06/2010 - 11/2006)
10.	Moss, Neil: 2 articles (02/2007 - 10/2003)

Related Diseases

1.	Crohn Disease (Crohn's Disease) 03/01/2006 - "No clinical efficacy (primary end point, clinical remission; secondary end point, clinical response; Inflammatory Bowel Disease Questionnaire; Crohn's Disease Endoscopic Index of Severity) was seen for BIRB 796 in comparison with placebo. " 03/01/2006 - "Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial." 10/01/2011 - "Levels of alanine transaminase, a biomarker of hepatic toxicity in clinical pathology, were found to be increased in Crohn's disease patients treated with BIRB-796. "
2.	Vascular Remodeling 07/01/2016 - "In addition, BIRB796 treatment improved vascular remodeling by reducing the aortic media-to-lumen ratio and decreasing the expression of the membrane metalloproteinases (MMP) MMP-1 and MMP-9. "
3.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 03/01/2006 - "No clinical efficacy (primary end point, clinical remission; secondary end point, clinical response; Inflammatory Bowel Disease Questionnaire; Crohn's Disease Endoscopic Index of Severity) was seen for BIRB 796 in comparison with placebo. "
4.	Glaucoma 01/01/2020 - "Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma." 01/01/2020 - "Here, we assessed the neuroprotective effect of topical eye delivery of the p38 MAPK inhibitor BIRB 796 in three models of glaucoma (microbead occlusion in rat and squirrel monkey and the genetic DBA/2 J mouse model) with distinct durations of IOP elevation. "
5.	Chronic Obstructive Pulmonary Disease (COPD) 10/01/2017 - "RV568 was evaluated in a 14-day trial in COPD patients.RV568 showed potent anti-inflammatory effects in monocytes and macrophages, which were often greater than those of corticosteroids or the p38 inhibitor Birb796. " 01/01/2017 - "Alveolar macrophages from COPD patients and controls were exposed to NTHi in conjunction with the corticosteroid dexamethasone and/or the p38 MAPK inhibitor BIRB-796. " 11/22/2019 - "Cultivated HASMCs from COPD subjects were pre-incubated with formoterol, salmeterol, fluticasone-propionate, BIRB796 (p38MAPKα, -γ, -δ inhibitor), and/or SB203580 (p38MAPKα and -β inhibitor) before stimulation with TNFα or LPS. " 11/13/2012 - "In this study, we compared the ability of the phosphodiesterase IV (PDEIV) inhibitor Cilomilast, the steroid Budesonide, and the p38 mitogen activated protein kinase inhibitor BIRB-796 to inhibit tumour necrosis factor alpha (TNFα) and interleukin 6 (IL-6) releases from AMs isolated from COPD lung transplant tissue. " 06/01/2016 - "Blood and sputum neutrophils from stable and exacerbating COPD patients were cultured with the corticosteroid dexamethasone, a pan PI3 kinase inhibitor (ZSTK474), a δ selective PI3 kinase inhibitor (GSK045) and a p38 mitogen activated protein (MAP) kinase inhibitor (BIRB 796); matrix metalloproteinase (MMP)-9 and reactive oxygen species (ROS) release were analysed. "

Related Drugs and Biologics

1.	Matrix Metalloproteinases (MMPs)
2.	Metalloproteases (Metalloproteinases)
3.	p38 Mitogen-Activated Protein Kinases
4.	Mitogen-Activated Protein Kinase 14
5.	Urea (Carbamide)
6.	Interleukin-6 (Interleukin 6)
7.	Adrenal Cortex Hormones (Corticosteroids)
8.	SB 203580
9.	Type 4 Cyclic Nucleotide Phosphodiesterases
10.	Budesonide (Pulmicort)

Related Therapies and Procedures

1.	Therapeutics
2.	Microspheres (Microsphere)